CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade DexCom, Inc. - DXCM CFD

106.51
2.49%
0.27
Low: 104.48
High: 106.71
Market Trading Hours* (UTC) Opens on Friday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.27
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.030779 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.030779%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.013666 %
Charges from borrowed part ($-0.55)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.013666%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Dexcom Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 103.92
Open* 104.5
1-Year Change* -74.25%
Day's Range* 104.48 - 106.71
52 wk Range 66.89-154.52
Average Volume (10 days) 2.44M
Average Volume (3 months) 59.24M
Market Cap 42.88B
P/E Ratio 207.35
Shares Outstanding 386.26M
Revenue 2.79B
EPS 0.54
Dividend (Yield %) N/A
Beta 1.15
Next Earnings Date Feb 8, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jan 26, 2023 106.51 1.61 1.53% 104.90 106.94 103.66
Jan 25, 2023 103.92 0.84 0.81% 103.08 104.87 102.36
Jan 24, 2023 105.89 0.74 0.70% 105.15 106.36 102.52
Jan 23, 2023 106.25 -0.75 -0.70% 107.00 108.73 105.87
Jan 20, 2023 107.72 1.88 1.78% 105.84 107.91 104.65
Jan 19, 2023 106.01 0.12 0.11% 105.89 107.57 105.56
Jan 18, 2023 106.54 -2.35 -2.16% 108.89 110.13 106.33
Jan 17, 2023 109.39 2.37 2.21% 107.02 109.54 105.38
Jan 13, 2023 108.28 2.72 2.58% 105.56 108.52 104.94
Jan 12, 2023 107.03 1.74 1.65% 105.29 108.38 103.20
Jan 11, 2023 106.04 -5.64 -5.05% 111.68 112.32 104.94
Jan 10, 2023 110.78 2.23 2.05% 108.55 111.86 107.67
Jan 9, 2023 109.89 -1.90 -1.70% 111.79 113.12 107.21
Jan 6, 2023 115.67 3.49 3.11% 112.18 116.86 110.41
Jan 5, 2023 111.58 -1.64 -1.45% 113.22 113.98 110.28
Jan 4, 2023 114.21 -2.62 -2.24% 116.83 117.46 113.14
Jan 3, 2023 114.63 0.22 0.19% 114.41 115.98 111.98
Dec 30, 2022 113.14 3.14 2.85% 110.00 113.23 109.03
Dec 29, 2022 111.96 2.45 2.24% 109.51 113.25 109.00
Dec 28, 2022 109.71 0.50 0.46% 109.21 111.64 108.84

DexCom, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 573.3 718.5 1031.6 1476 1926.7 2448.5
Revenue 573.3 718.5 1031.6 1476 1926.7 2448.5
Cost of Revenue, Total 194.9 226.4 367.7 530.4 622.2 739.9
Gross Profit 378.4 492.1 663.9 945.6 1304.5 1708.6
Total Operating Expense 637.2 761 1217.9 1333.7 1633.1 2184.2
Selling/General/Admin. Expenses, Total 286.2 349.2 432.8 515.7 620.7 810.5
Research & Development 156.1 185.4 417.4 273.5 359.9 604.2
Operating Income -63.9 -42.5 -186.3 142.3 293.6 264.3
Interest Income (Expense), Net Non-Operating -0.3 -9.5 59.8 -38.1 -68.6 -90.4
Other, Net -0.7 3.4
Net Income Before Taxes -64.9 -48.6 -126.5 104.2 225 173.9
Net Income After Taxes -65.6 55.5 -127.5 101.1 493.6 154.7
Net Income Before Extra. Items -65.6 55.5 -127.5 101.1 493.6 154.7
Net Income -65.6 -50.2 -127.1 101.1 493.6 154.7
Income Available to Common Excl. Extra. Items -65.6 55.5 -127.5 101.1 493.6 154.7
Income Available to Common Incl. Extra. Items -65.6 -50.2 -127.1 101.1 493.6 154.7
Diluted Net Income -65.6 -50.2 -127.1 101.1 493.6 154.7
Diluted Weighted Average Shares 334.4 345.2 352.8 369.2 390 400.4
Diluted EPS Excluding Extraordinary Items -0.19617 0.16078 -0.36139 0.27384 1.26564 0.38636
Dividends per Share - Common Stock Primary Issue 0
Diluted Normalized EPS -0.19617 0.18149 -0.35145 0.33848 1.33881 0.50656
Total Extraordinary Items -105.7 0.4 0
Unusual Expense (Income) 14.1 30.3 29.6
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 505 595.1 650.2 698.2 628.8
Revenue 505 595.1 650.2 698.2 628.8
Cost of Revenue, Total 161.1 178 203.3 197.5 230.7
Gross Profit 343.9 417.1 446.9 500.7 398.1
Total Operating Expense 459.1 494.1 532.7 698.3 587.5
Selling/General/Admin. Expenses, Total 188.6 187 199.8 235.1 220.9
Research & Development 109.4 129.1 128.8 236.9 135.9
Operating Income 45.9 101 117.5 -0.1 41.3
Interest Income (Expense), Net Non-Operating -4.6 -24.3 -26.8 -14.6 -5.2
Net Income Before Taxes 41.3 76.7 90.7 -14.7 36.1
Net Income After Taxes 56.5 62.9 70.9 -19.4 97.3
Net Income Before Extra. Items 56.5 62.9 70.9 -19.4 97.3
Net Income 56.5 62.9 70.9 -19.4 97.3
Income Available to Common Excl. Extra. Items 56.5 62.9 70.9 -19.4 97.3
Income Available to Common Incl. Extra. Items 56.5 62.9 70.9 -19.4 97.3
Diluted Net Income 56.5 62.9 70.9 -19.4 97.3
Diluted Weighted Average Shares 418.4 398.4 402 388 428.8
Diluted EPS Excluding Extraordinary Items 0.13504 0.15788 0.17637 -0.05 0.22691
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.13504 0.15788 0.17792 -0.00175 0.22691
Unusual Expense (Income) 0 0.8 28.8
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 280 744.7 1699.5 1969.4 3424.8 3684.4
Cash and Short Term Investments 123.7 548.6 1385.6 1533.3 2707.7 2731.2
Cash & Equivalents 94.5 441.5 1137 446.2 817.6 1052.6
Short Term Investments 29.2 107.1 248.6 1087.1 1890.1 1678.6
Total Receivables, Net 101.7 134.3 226.7 286.3 428.5 514.3
Accounts Receivable - Trade, Net 101.7 134.3 226.7 286.3 428.5 514.3
Total Inventory 45.4 45.2 70.7 119.8 234.7 357.3
Prepaid Expenses 9.2 16.6 16.5 30 53.9 81.6
Total Assets 402.8 904.1 1916 2395 4290.5 4933.3
Property/Plant/Equipment, Total - Net 109.4 145.6 183.1 392.8 608.6 889.9
Property/Plant/Equipment, Total - Gross 156.6 200.4 262.9 497.8 762.8 1121.4
Accumulated Depreciation, Total -47.2 -54.8 -79.8 -105 -154.2 -231.5
Goodwill, Net 11.3 12.1 18.7 18.6 19.3 26.5
Intangibles, Net 0.2 31.5
Other Long Term Assets, Total 1.9 1.7 14.7 14.2 237.8 301
Total Current Liabilities 102.4 138.9 222.4 360.2 614.1 720.8
Accounts Payable 24.5 46.7 75.5 102.3 163.3 189.4
Accrued Expenses 77 89 144 255.6 439.8 514.3
Notes Payable/Short Term Debt 0 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 0.6 8.8
Other Current Liabilities, Total 0.9 3.2 2.9 1.7 2.2 17.1
Total Liabilities 119 484.7 1252.7 1512.4 2464 2891.2
Total Long Term Debt 6 334.3 1017.6 1074.1 1721.2 2038.8
Long Term Debt 0 327.6 1010.3 1059.7 1667.2 1981.8
Capital Lease Obligations 6 6.7 7.3 14.4 54 57
Other Liabilities, Total 10.6 11.5 12.7 78.1 128.7 125.7
Total Equity 283.8 419.4 663.3 882.6 1826.5 2042.1
Redeemable Preferred Stock 0 0 0 0 0 0
Common Stock 0.1 0.1 0.1 0.1 0.1 0.1
Additional Paid-In Capital 905.7 1093.7 1560.6 1675.9 2125.3 2109
Retained Earnings (Accumulated Deficit) -621 -671.8 -798.9 -695.7 -202.1 138.7
Other Equity, Total -1 -2.6 1.5 2.3 3.2 0.5
Total Liabilities & Shareholders’ Equity 402.8 904.1 1916 2395 4290.5 4933.3
Total Common Shares Outstanding 338.4 348 360 366.4 384.4 388
Treasury Stock - Common -100 -100 -100 -206.2
Deferred Income Tax 5.9
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 3445.1 3474.2 3656.2 3684.4 3746.6
Cash and Short Term Investments 2632.6 2584.9 2697.9 2731.2 2688.2
Cash & Equivalents 733.8 1158.8 1444.3 1052.6 716
Short Term Investments 1898.8 1426.1 1253.6 1678.6 1972.2
Total Receivables, Net 443.4 483.5 529.1 514.3 544.5
Accounts Receivable - Trade, Net 443.4 483.5 529.1 514.3 544.5
Total Inventory 289.7 319.3 351.3 357.3 342.2
Prepaid Expenses 79.4 86.5 77.9 81.6 171.7
Total Assets 4389.8 4503.8 4775.9 4933.3 5057
Property/Plant/Equipment, Total - Net 688.7 770.8 833.5 889.9 938.8
Property/Plant/Equipment, Total - Gross 860.7 957.6 1036.5 1121.4 1203.7
Accumulated Depreciation, Total -172 -186.8 -203 -231.5 -264.9
Goodwill, Net 18.9 19.1 23.9 26.5 26.6
Other Long Term Assets, Total 237.1 239.7 238.9 301 313.6
Total Current Liabilities 604.1 600.7 734.9 720.8 711.4
Accounts Payable 152.2 165.9 210 189.4 150.1
Accrued Expenses 450 433 522.6 514.3 558.6
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 1.9 1.8 2.3 17.1 2.7
Total Liabilities 2486.6 2506.2 2639.8 2891.2 2867.7
Total Long Term Debt 1743 1768.1 1761.3 2038.8 2027.5
Long Term Debt 1688.8 1710.7 1703.5 1981.8 1965.9
Capital Lease Obligations 54.2 57.4 57.8 57 61.6
Other Liabilities, Total 139.5 137.4 143.6 125.7 122.7
Total Equity 1903.2 1997.6 2136.1 2042.1 2189.3
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.1 0.1 0.1 0.1 0.1
Additional Paid-In Capital 2162 2193.6 2322.1 2109 1996.6
Retained Earnings (Accumulated Deficit) -161.8 -98.9 -28 138.7 236
Treasury Stock - Common -100 -100 -159.5 -206.2 -37.3
Other Equity, Total 2.9 2.8 1.4 0.5 -6.1
Total Liabilities & Shareholders’ Equity 4389.8 4503.8 4775.9 4933.3 5057
Total Common Shares Outstanding 386.8 386.8 387.6 388 392.4
Intangibles, Net 23.4 31.5 31.4
Deferred Income Tax 5.9 6.1
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -65.6 -50.2 -127.1 101.1 493.6 154.7
Cash From Operating Activities 56.2 92 123.2 314.5 475.6 442.5
Cash From Operating Activities 15 16.1 29.1 48.7 67.1 102
Non-Cash Items 113.1 123.5 262.1 158.6 213 322.7
Cash Taxes Paid 0.1 1.4 2.3 4.8 3.6 16.8
Cash Interest Paid 0.1 2.4 3.6 10.4 10.6 11.6
Changes in Working Capital -6.3 2.6 -40.9 6.1 -20.8 -132
Cash From Investing Activities -55.9 -144.4 -139.8 -1015.2 -1018 -216.1
Capital Expenditures -55.7 -66 -67.1 -180 -199 -389.2
Other Investing Cash Flow Items, Total -0.2 -78.4 -72.7 -835.2 -819 173.1
Cash From Financing Activities 8.1 399.1 710.4 10.7 912.1 10.4
Issuance (Retirement) of Stock, Net 10.4 10.1 94.6 11.9 15.3 20.3
Issuance (Retirement) of Debt, Net -2.3 389 617.7 0 906.2 0
Net Change in Cash 8.4 347 695.6 -690.7 371.8 235.4
Foreign Exchange Effects 0.3 1.8 -0.7 2.1 -1.4
Financing Cash Flow Items -1.9 -1.2 -9.4 -9.9
Deferred Taxes -277.3 -4.9
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line 40.3 103.2 174.1 154.7 97.3
Cash From Operating Activities 27.8 89.4 336.7 442.5 71
Cash From Operating Activities 20.9 44.4 69.9 102 36.8
Deferred Taxes -0.3 0.1 0.2 -4.9 0.1
Non-Cash Items 58.2 120.3 185.1 322.7 34.3
Changes in Working Capital -91.3 -178.6 -92.6 -132 -97.5
Cash From Investing Activities -112.2 251 280 -216.1 -411.8
Capital Expenditures -99.7 -200.9 -309 -389.2 -101.6
Other Investing Cash Flow Items, Total -12.5 451.9 589 173.1 -310.2
Cash From Financing Activities 0.8 0.4 11.2 10.4 5.3
Financing Cash Flow Items -7.9 -8.3 -9.1 -9.9 -4.8
Issuance (Retirement) of Stock, Net 8.7 8.7 20.3 20.3 10.1
Foreign Exchange Effects -0.4 0.1 -0.9 -1.4 -1
Net Change in Cash -84 340.9 627 235.4 -336.5
Issuance (Retirement) of Debt, Net 0 0 0
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 11.263 43504103 506655 2022-09-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 5.6274 21736347 -75610 2022-09-30 LOW
Baillie Gifford & Co. Investment Advisor 4.4796 17302885 -802293 2022-12-31 LOW
Sands Capital Management, LLC Investment Advisor 4.3218 16693318 -1208895 2022-09-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.2437 16391712 156880 2022-09-30 LOW
Capital Research Global Investors Investment Advisor 2.7262 10530238 2847171 2022-09-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 2.5609 9891601 -119599 2022-09-30 LOW
Wellington Management Company, LLP Investment Advisor/Hedge Fund 2.3422 9047009 3297715 2022-09-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 2.0751 8015184 192962 2022-09-30 LOW
Nuveen LLC Pension Fund 2.0577 7948042 209503 2022-09-30 LOW
JP Morgan Asset Management Investment Advisor 1.8817 7268168 -646636 2022-09-30 LOW
Jennison Associates LLC Investment Advisor/Hedge Fund 1.7976 6943376 -1620235 2022-09-30 LOW
ClearBridge Investments, LLC Investment Advisor/Hedge Fund 1.4004 5408974 -298536 2022-09-30 LOW
Invesco Capital Management (QQQ Trust) Investment Advisor 1.334 5152750 -589239 2022-12-31 LOW
Janus Henderson Investors Investment Advisor/Hedge Fund 1.265 4886021 -1210023 2022-09-30 LOW
William Blair & Company, L.L.C. (Research) Research Firm 1.1965 4621748 119780 2022-09-30 LOW
Voya Investment Management LLC Investment Advisor/Hedge Fund 1.1531 4454124 1510296 2022-09-30 MED
Capital World Investors Investment Advisor 0.9751 3766229 47344 2022-09-30 LOW
Macquarie Investment Management Investment Advisor 0.9446 3648714 374085 2022-09-30 LOW
T. Rowe Price Associates, Inc. Investment Advisor 0.8992 3473151 -620387 2022-09-30 LOW

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
+485000+

Traders

65000+

Active clients monthly

$48000000+

Monthly investing volume

$28000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

DexCom Company profile

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Industry: Medical Equipment, Supplies & Distribution (NEC)

6340 Sequence Dr
SAN DIEGO
CALIFORNIA 92121
US

Income Statement

  • Annual
  • Quarterly

People also watch

Natural Gas

2.81 Price
-0.950% 1D Chg, %
Long position overnight fee 0.0876%
Short position overnight fee -0.1228%
Overnight fee time 22:00 (UTC)
Spread 0.005

US100

11,990.00 Price
-0.110% 1D Chg, %
Long position overnight fee -0.0179%
Short position overnight fee 0.0070%
Overnight fee time 22:00 (UTC)
Spread 1.8

ETH/USD

1,580.94 Price
-1.590% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 5.00

XRP/USD

0.41 Price
-1.040% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 0.00336

Still looking for a broker you can trust?

Join the 480.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading